RGD Reference Report - Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke? - Rat Genome Database
Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?

Authors: Irving, EA  Vinson, M  Rosin, C  Roberts, JC  Chapman, DM  Facci, L  Virley, DJ  Skaper, SD  Burbidge, SA  Walsh, FS  Hunter, AJ  Parsons, AA 
Citation: Irving EA, etal., J Cereb Blood Flow Metab. 2005 Jan;25(1):98-107.
RGD ID: 9685232
Pubmed: (View Article at PubMed) PMID:15678116
DOI: Full-text: DOI:10.1038/sj.jcbfm.9600011

The inhibitory activity of myelin-associated glycoprotein (MAG) on neurons is thought to contribute to the lack of regenerative capacity of the CNS after injury. The interaction of MAG and its neuronal receptors mediates bidirectional signaling between neurons and oligodendrocytes. The novel finding that an anti-MAG monoclonal antibody not only possesses the ability to neutralise the inhibitory effect of MAG on neurons but also directly protects oligodendrocytes from glutamate-mediated oxidative stress-induced cell death is reported here. Furthermore, administration of anti-MAG antibody (centrally and systemically) starting 1 hour after middle cerebral artery occlusion in the rat significantly reduced lesion volume at 7 days. This neuroprotection was associated with a robust improvement in motor function compared with animals receiving control IgG1. Together, these data highlight the potential for the use of anti-MAG antibodies as therapeutic agents for the treatment of stroke.

Annotation

Disease Annotations    

Objects Annotated

Genes (Rattus norvegicus)
Mag  (myelin-associated glycoprotein)

Genes (Mus musculus)
Mag  (myelin-associated glycoprotein)

Genes (Homo sapiens)
MAG  (myelin associated glycoprotein)


Additional Information